Abstract: Docetaxel is a cornerstone chemotherapeutic agent in the management of advanced prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). As an anti-mitotic taxane, it exerts its antitumor effects by binding to the beta-subunit of tubulin, stabilizing microtubules, and inducing apoptosis through cell cycle arrest at the G2/M phase. Despite its proven survival benefits in landmark trials such as CHAARTED and STAMPEDE, the clinical utility of docetaxel is frequently hindered by dose-limiting toxicities, such as neutropenia and lymphopenia, and the inevitable development of drug resistance. Resistance mechanisms are multifaceted, involving drug efflux pumps (e.g., P-glycoprotein/ABCB1), tubulin mutations, and the activation of alternative survival pathways (e.g., NF-κB, STAT). Furthermore, cross-resistance with androgen receptor-targeted agents poses significant challenges in treatment sequencing. To overcome these limitations, recent research has focused on treatment intensification strategies, such as triplet therapies combining docetaxel with androgen deprivation therapy (ADT) and androgen receptor-targeted agents (ARTA), as well as the development of advanced nanoplatforms for targeted drug delivery. This review synthesizes current literature on the pharmacological activity, molecular mechanisms, limitations, and future perspectives of docetaxel in the context of castration-resistant prostate cancer.
1. Introduction
Prostate adenocarcinoma is a leading cause of cancer-related morbidity and mortality in men. While early-stage disease is often manageable, a significant proportion of patients progress to advanced or metastatic stages [1]. The historical standard of care for advanced prostate cancer has been androgen-deprivation therapy (ADT); however, despite initial responses, the disease inevitably progresses to a castration-resistant state within a few years [1][6]. Metastatic castration-resistant prostate cancer (mCRPC) is defined by disease progression despite castrate levels of circulating testosterone, driven by mechanisms such as androgen receptor (AR) amplification, mutations, and altered steroidogenesis [1].
Docetaxel, a well-established anti-mitotic chemotherapeutic agent, has long been a primary standard of care for patients with mCRPC, offering significant survival advantages over older regimens like mitoxantrone [1][3]. In recent years, the treatment landscape has expanded to include novel androgen receptor signaling inhibitors (ARSIs) and targeted therapies, shifting the paradigm of how and when docetaxel is utilized in the clinical sequencing of prostate cancer therapies [2][6].
2. Pharmacological Activity
Docetaxel has demonstrated robust pharmacological efficacy in both hormone-sensitive and castration-resistant settings. Landmark phase III trials, including CHAARTED and STAMPEDE, established that the addition of docetaxel to ADT provides a substantial survival benefit—up to a 17-month advantage in hormone-naïve patients with high-volume or visceral metastases [1][4]. Recent meta-analyses have further validated treatment intensification strategies, showing that a "triplet" combination of an ARTA (such as abiraterone, enzalutamide, apalutamide, or darolutamide), docetaxel, and ADT significantly prolongs overall survival (OS) and progression-free survival (PFS) compared to docetaxel and ADT alone, reducing the risk of death by approximately 26% [6].
Pharmacokinetically, docetaxel distributes rapidly from the body's core to its extremities. However, its oral bioavailability is exceptionally poor (less than 10%) due to a high concentration of P-glycoprotein in the gastrointestinal tract, which has a strong binding affinity for the drug [5]. Consequently, docetaxel is administered intravenously. It is primarily metabolized in the liver and excreted through the kidneys, intestines, and bile [5].
3. Molecular Mechanism of Action
Docetaxel exerts its antitumor activity primarily through the disruption of the microtubule network, which is essential for cancer cell division, signaling, migration, and metastasis [5]. The drug binds specifically to the beta-subunit of free tubulin heterodimers, promoting their assembly into stable microtubules and preventing their subsequent depolymerization [1][5]. This stabilization inhibits normal dynamic reorganization of the microtubule network, effectively arresting the cell cycle at the G2/M phase and inhibiting mitosis [1][5].
Beyond its mechanical disruption of mitosis, docetaxel actively induces apoptosis. It inhibits the activation of anti-apoptotic genes, specifically Bcl-2 and Bcl-xL, and boosts the production of the cell cycle inhibitor p27 [5]. Furthermore, docetaxel's stabilization of microtubules indirectly abrogates androgen receptor nuclear translocation, thereby interfering with AR-mediated transcription, which is a critical survival pathway in prostate cancer cells [1][6].
4. Structure-Activity Relationship (SAR)
While detailed structural modifications are beyond the scope of the provided literature, the structure-activity relationship of docetaxel is highlighted by its binding affinities. Docetaxel possesses a twofold higher binding affinity to tubulin compared to its predecessor, paclitaxel, which is a primary reason for its enhanced antineoplastic performance [5]. Additionally, its molecular structure exhibits a strong tendency to bind to ATP-binding cassette (ABC) transporters, particularly P-glycoprotein (ABCB1). While this affinity limits its oral bioavailability, it also forms the basis for one of the primary mechanisms of acquired drug resistance [1][5].
5. Current Limitations
The clinical efficacy of docetaxel is significantly limited by systemic toxicity and the emergence of drug resistance.
Toxicity: Docetaxel treatment is associated with severe adverse events (AEs). The most common grade 3 or higher AEs include neutropenia, lymphopenia, leukopenia, and back pain [2]. The immunosuppressive nature of docetaxel, often exacerbated by the concomitant use of steroids (e.g., prednisone or dexamethasone), has also raised concerns during the COVID-19 pandemic, leading experts to recommend avoiding taxane treatment during pandemic peaks for unvaccinated patients due to the negative impact on viral infection outcomes [7].
Drug Resistance: Resistance to docetaxel in CRPC is multifactorial. A primary mechanism is drug efflux mediated by the upregulation of multi-drug resistant proteins, notably P-glycoprotein (ABCB1) [1]. Additionally, the upregulation of the class III beta-tubulin isoform creates less stable microtubules, counteracting docetaxel's stabilizing effect [1]. Prostate cancer cells also evade docetaxel-induced apoptosis through the upregulation of p53, activation of PAR1 (which limits apoptosis via NF-κB), and the overexpression of chaperone proteins like HSP27, HSP90, and clusterin [1]. Furthermore, docetaxel's antimitotic activity can paradoxically induce survival pathways, such as the c-Jun N-terminal kinase pathway, leading to the activation of transcription factors like STAT-1, STAT-3, and NF-κB [1].
Cross-Resistance: Sequencing therapies in mCRPC is complicated by cross-resistance between docetaxel and AR-targeted therapies (e.g., abiraterone and enzalutamide). Prior treatment with abiraterone or docetaxel blunts the subsequent efficacy of enzalutamide, and conversely, taxane efficacy is reduced following AR-targeted therapy, likely because both therapeutic classes converge on disrupting AR nuclear translocation [1].
6. Future Perspectives
To overcome the limitations of docetaxel, current research is heavily focused on novel drug delivery systems and combination therapies.
Nanotechnology: Nanoplatforms are being developed to enhance the solubility, bioavailability, and targeted release of docetaxel while minimizing systemic toxicity [5]. Examples include biomimetic nanoparticles coated with homotypic tumor cell membranes (TCM) that improve tumor accumulation and reduce off-target toxicity [5]. Other innovations include lactoferrin-loaded nanoparticles, titanate nanotubes engineered with gold nanoparticles for combined radiotherapy and chemotherapy, and PLGA polymeric nanoparticles co-encapsulating docetaxel and abiraterone acetate to achieve synergistic effects [5].
Combination Therapies: The future of CRPC management lies in rational combination strategies. Triplet therapies combining docetaxel, ADT, and ARSIs have already shown superiority over doublet therapies in hormone-sensitive settings [6]. Furthermore, combining docetaxel with novel agents, such as PARP inhibitors (e.g., olaparib, niraparib) or autophagy inhibitors, represents a promising frontier to bypass resistance mechanisms and improve survival outcomes in patients with advanced prostate cancer [1][2].
